Taysha Gene Therapies (TSHA)

• Market cap: $1.27B
• 1 day: -4.54%
• 5 days: -1.12%
• 1 month: -3.28%
• 3 months: -9.05%
• 6 months: -9.43%
• Year to date: -15.81%
• 1 year: 277.78%
• 5 years: -82.32%
• 10 years: -81.63%
• Sector: Healthcare
• Industry: Biotechnology

About: Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Employees: 99